Naxozole (esomeprazole/naproxen)
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 07, 2024
LBP: A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients
(clinicaltrials.gov)
- P3 | N=286 | Recruiting | Sponsor: Hanmi Pharmaceutical Company Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Head-to-Head • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain
September 19, 2024
LBP: A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients
(clinicaltrials.gov)
- P3 | N=286 | Not yet recruiting | Sponsor: Hanmi Pharmaceutical Company Limited
Head-to-Head • New P3 trial • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain
September 02, 2021
Multivariate Assessment for Bioequivalence Based on the Correlation of Random Effect.
(PubMed, Drug Des Devel Ther)
- "Three pharmacokinetic datasets, fixed-dose combination (naproxen and esomeprazole), tramadol and fimasartan data were analyzed. This multivariate HGLM had good performance in the bioequivalence test with multiple endpoints. This method would provide a more reasonable option to reduce the 90% CI by adding correlation parameters and thus an advantage especially in evaluating the bioequivalence of highly variable drugs with broad 90% CIs."
Journal
1 to 3
Of
3
Go to page
1